Regeneron Pharmaceuticals Inc
REGN545.460USD
-9.120-1.64%
Close 07/31, 16:00（ET）Quotes delayed by 15 min
59.02BMarket Cap
13.12P/E TTM
More Details of Regeneron Pharmaceuticals Inc Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
Ticker SymbolREGN
Company nameRegeneron Pharmaceuticals Inc
IPO dateApr 02, 1991
Founded at1988
CEODr. Leonard S. Schleifer, M.D., Ph.D
Number of employees15106
Security typeOrdinary Share
Fiscal year-endApr 02
Address777 Old Saw Mill River Road
CityTARRYTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10591
Phone17813705000
Websitehttps://www.regeneron.com/
Ticker SymbolREGN
IPO dateApr 02, 1991
Founded at1988
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.42K
+0.05%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
19.75K
+20.78%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.37K
+9.94%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.42K
+0.05%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Sanofi
1.18B
39.07%
EYLEA
736.00M
24.30%
Bayer
343.90M
11.35%
EYLEA HD
306.80M
10.13%
Libtayo
192.50M
6.36%
Other
266.30M
8.79%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sanofi
1.18B
39.07%
EYLEA
736.00M
24.30%
Bayer
343.90M
11.35%
EYLEA HD
306.80M
10.13%
Libtayo
192.50M
6.36%
Other
266.30M
8.79%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.81%
Fidelity Management & Research Company LLC
6.97%
BlackRock Institutional Trust Company, N.A.
5.41%
State Street Global Advisors (US)
4.51%
JP Morgan Asset Management
3.84%
Other
70.45%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.81%
Fidelity Management & Research Company LLC
6.97%
BlackRock Institutional Trust Company, N.A.
5.41%
State Street Global Advisors (US)
4.51%
JP Morgan Asset Management
3.84%
Other
70.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.60%
Investment Advisor/Hedge Fund
25.32%
Hedge Fund
3.50%
Pension Fund
2.69%
Research Firm
2.61%
Bank and Trust
2.00%
Individual Investor
1.97%
Sovereign Wealth Fund
1.14%
Insurance Company
0.07%
Other
6.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
2575
99.67M
93.89%
-1.72M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
2023Q1
2366
99.66M
92.70%
-1.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.36M
8.81%
+117.55K
+1.27%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.40M
6.97%
-573.19K
-7.19%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.74M
5.41%
+45.93K
+0.81%
Mar 31, 2025
State Street Global Advisors (US)
4.79M
4.51%
-42.58K
-0.88%
Mar 31, 2025
JP Morgan Asset Management
4.08M
3.84%
-1.16M
-22.19%
Mar 31, 2025
Capital International Investors
3.99M
3.76%
-747.80K
-15.79%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.47M
2.33%
+41.95K
+1.73%
Mar 31, 2025
Dodge & Cox
2.32M
2.19%
+2.77K
+0.12%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
2.19M
2.07%
-36.81K
-1.65%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.02M
1.9%
+85.41K
+4.41%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
6.29%
Tema Neuroscience and Mental Health ETF
6.17%
Invesco Nasdaq Biotechnology ETF
5.92%
iShares Biotechnology ETF
5.46%
VanEck Biotech ETF
4.39%
iShares Genomics Immunology and Healthcare ETF
4.27%
Invesco Biotechnology & Genome ETF
3.61%
Simplify Health Care ETF
3.06%
Franklin Genomic Advancements ETF
2.97%
First Trust NASDAQ Pharmaceuticals ETF
2.84%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion6.29%
Tema Neuroscience and Mental Health ETF
Proportion6.17%
Invesco Nasdaq Biotechnology ETF
Proportion5.92%
iShares Biotechnology ETF
Proportion5.46%
VanEck Biotech ETF
Proportion4.39%
iShares Genomics Immunology and Healthcare ETF
Proportion4.27%
Invesco Biotechnology & Genome ETF
Proportion3.61%
Simplify Health Care ETF
Proportion3.06%
Franklin Genomic Advancements ETF
Proportion2.97%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
